Severe Fulminant Acute Disseminated Encephalomyelitis (ADEM) in an 18-Year-Old

Abstract

Background: Acute disseminated encephalomyelitis (ADEM) is a rare demyelinating disease of the central nervous system usually preceded by an infection. While mainly a childhood disease, ADEM carries a worse prognosis in adults. We present a case of severe fulminant ADEM in an 18-year-old patient resulting in rapid neurological injury. Case Report: An 18-year-old woman presented to our emergency room with fever and an altered level of consciousness followed by a generalized tonic-clonic seizure. Cerebrospinal fluid (CSF) findings were initially suggestive of meningitis; however, subsequent neuroimaging and laboratory evaluation favored a diagnosis of acute disseminated encephalomyelitis. Despite treatment with broad-spectrum antimicrobials and high-dose corticosteroids, the patient experienced rapid neurological deterioration, culminating in extensive and irreversible brain injury. Conclusion: Prompt diagnosis and treatment of ADEM, particularly in the adult population, remains a significant clinical challenge. Our case underscores the need for heightened vigilance and continued research to assist clinicians in the time-sensitive identification of this severe demyelinating disease.

Share and Cite:

Zaid, A.H. and Warmus, B.A. (2026) Severe Fulminant Acute Disseminated Encephalomyelitis (ADEM) in an 18-Year-Old. Neuroscience and Medicine, 17, 37-45. doi: 10.4236/nm.2026.171004.

1. Introduction

Acute disseminated encephalomyelitis (ADEM) is a rare immune-mediated demyelinating disorder of the central nervous system, most commonly associated with a preceding infection [1]. Usually seen in childhood following viral infections, it has a more severe course and is associated with a worse outcome in adults [2]. Here, we describe an 18-year-old patient with a fulminant case of ADEM resulting in rapid neurological deterioration.

2. Case Report

An 18-year-old woman with no significant medical history presented to our emergency room after a generalized tonic-clonic seizure following a two-day history of fever and confusion. She had no history of recent travel or substance use and had no sick contacts.

On evaluation in the ER, she was found to be drowsy but arousable, aphasic, and unable to follow simple commands. She had erythema of the oropharynx but no neck stiffness. After a CT head revealed no abnormalities, a lumbar puncture was performed, and she was administered empiric antimicrobials to treat meningitis along with anti-epileptic agents. Cerebrospinal fluid (CSF) analysis showed an elevated white cell count with a neutrophilic predominance; CSF protein was abnormally high, and CSF glucose was within the normal range (Table 1). Despite the normal glucose, the overall CSF profile was initially concerning for meningitis, and antimicrobial therapy was therefore continued. Aside from mild leukocytosis, complete blood counts, serum chemistry, toxicology screen, and respiratory viral panel were all unremarkable.

Table 1. Cerebrospinal fluid analysis.

CSF analysis

Color

Colorless

Turbidity

Clear

Protein

479 mg/dL

Glucose

108 mg/dL

Concurrent blood glucose

190 mg/dL

Red blood cells

53/mm3

Nucleated cells

274/mm3

Polymorphonuclear cells

76 %

Lymphocytes

5 %

Mononuclear cells

19 %

Due to increasing obtundation and hypoxemia, the patient underwent tracheal intubation later the same day. An MRI of the brain showed multiple bilateral periventricular white matter lesions (Figure 1(A), Figure 1(D), Figure 1(E) and Figure 2(A)) along with areas of increased T2 signal with restricted diffusion (Figure 1(B) and Figure 1(C)). Also seen were small areas of hypointensity on susceptibility-weighted images consistent with microhemorrhages (Figure 2(B)). MRI of the spine showed multifocal areas of demyelination in the cervical and thoracic spinal cord (Figure 3 and Figure 4). High-dose steroids were initiated at this point due to suspicion for ADEM and rapid progression of the disease. A CT of the abdomen and pelvis showed mesenteric and retroperitoneal lymphadenopathy with no evidence of an occult malignancy.

Figure 1. Abnormal T2 hyperintensities and diffusion restriction on MRI brain. ((A) - (C), Axial slices of T2 FLAIR (A), diffusion-weighted imaging (B), and apparent diffusion coefficient (C) at the same level, showing small areas of diffusion restriction (red arrows) within the larger areas of T2 hyperintensities. (D)-(E), Sagittal T2 FLAIR at the level of the blue dotted line (D) and green dotted line (E) in A, further demonstrating the periventricular distribution of T2 hyperintensities.

Figure 2. Microhemorrhages in the areas of T2 hyperintensities. (A) and (B), Axial slices of T2 FLAIR sequences (A) and susceptibility-weighted imaging (B) at two different levels demonstrate the extent and variability of periventricular and juxtacortical T2 hyperintensities (A), with areas of hypointensity (B) inside (arrows) and outside (arrowhead) the areas of T2 hyperintensity.

Figure 3. Patchy T2 hyperintensities in the cervical spine on MRI. (A) and (B), Sagittal T2 STIR sequences in different sagittal planes show patchy areas of T2 hyperintensities (arrowheads). (C)-(E), Axial T2 sequences at the levels of the yellow (C), blue (D), and orange (E) dotted lines show areas of T2 hyperintensities (arrows).

Figure 4. T2 hyperintensities in the thoracic spine on MRI. A, Sagittal T2 sequence showing subtle T2 hyperintensity of the anterior spinal cord (arrowhead). (B) and (C), Axial T2 sequences at the levels of the yellow (B) and blue (C) dotted lines show areas of T2 hyperintensity in the left hemicord (arrows).

The next morning, the patient’s neurologic exam deteriorated with loss of cranial nerve reflexes, absence of spontaneous respiratory effort, and a lack of motor response. An urgent CT head revealed diffuse cerebral edema, with loss of ‘gray-white’ differentiation (Figure 5). Hypertonic saline was administered to reduce intracranial pressure; however, there was no clinical improvement. The patient’s family declined a decompressive hemicraniectomy and other invasive interventions. The patient was subsequently declared brain dead.

Figure 5. Diffuse cerebral edema on CT head. A-B, Axial sequences at different levels showing loss of gray-white differentiation ((A), (B)) and pseudosubarachnoid hemorrhage (B).

A comprehensive panel of serum and CSF studies—including autoimmune antibody testing, CSF cultures, serologic tests, metagenomic next-generation sequencing for DNA and RNA viruses, bacteria, fungi, and parasites, as well as blood cultures—eventually returned negative, with the exception of Epstein–Barr virus (EBV) serology indicating a recent infection, likely a few weeks prior to presentation (Table 2).

3. Discussion

The earliest descriptions of ADEM seem to date back to the 18th century [3]. Although its etiology has not been definitively established, the condition is believed to arise from molecular mimicry, typically following infection, resulting in autoimmune-mediated demyelination of the central nervous system [4].

The 2012 update from the International Pediatric Multiple Sclerosis Study Group (IPMSSG) established consensus definitions and diagnostic criteria for pediatric acquired demyelinating syndromes, including ADEM [5]. Adults and children with ADEM often differ in their clinical presentations, with adults more commonly exhibiting long-tract neurological signs, whereas children typically present with fever, encephalopathy, and meningeal features [6]. In the absence of formal adult-specific criteria, the IPMSSG criteria have been applied in the evaluation of ADEM in adult patients [7]. However, as adults with ADEM less commonly present with encephalopathy, the applicability of these criteria to adult patients is limited. Furthermore, given the rarity of ADEM in adults and the predominantly retrospective nature of available studies, formal adult-specific diagnostic criteria are not well established [8].

Table 2. Comprehensive list of CSF and serum studies. Note that all studies were negative except for the EBV serology panel, which indicated a recent infection in the prior 2 - 3 months, and positive parvovirus IgG, which indicated a prior exposure.

Comprehensive CSF and serum studies

CSF Studies

CSF Encephalopathy Antibody Panel

Herpes Simplex Type 1 PCR

Herpes Simplex Type 2 PCR

Enterovirus PCR

Cryptococcal antigen

West Nile IgG and IgM

VDRL

Meningitis/Encephalitis Panel by PCR

E. coli

Heomophilus influenza

Listeria monocytogenes

Neisseria meningitidis

Streptococcus agalactiae

Streptococcus pneumoniae

Cytomegalovirus

Enterovirus

HSV 1 & 2

Human herpesvirus 6

Human parechovirus

Varicella zoster virus

Cryptococcus neoformans/gattii

DelveBio mNGS

No DNA viruses, RNA viruses, bacteria, fungi, or parasites were detected.

1) α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antibody (AMPA-R Ab)

2) Amphiphysin Ab (Amphiphysin Ab)

3) Contactin-associated protein-like 2 antibody (CASPR2-IgG)

4) Collapsin response mediator protein 5 antibody (CRMP-5-IgG)

5) Gamma-aminobutyric acid type B receptor Ab (GABA-B-R Ab)

6) Glutamic acid decarboxylase 65 Ab (GAD65 Ab)

7) Glial fibrillary acidic protein antibody (GFAP Ab)

8) Leucine-rich glioma-inactivated 1 antibody (LGI1-IgG)

9) Metabotropic glutamate receptor 1 antibody (mGluR1 Ab)

10) N-Methyl-D-aspartate receptor Ab (NMDA-R Ab)

11) Purkinje cell cytoplasmic antibody type 1 (Anti-Yo) (PCA antibody type 1)

12) Purkinje cell cytoplasmic antibody type 2 (Anti-Ri) (PCA antibody type 2)

13) Purkinje cell cytoplasmic antibody type Tr (Anti-Tr) (PCA Type Tr)

14) Dipeptidyl-peptidase-like protein 6 antibody (DPPX Ab)

15) Neuronal intermediate filament antibody (NIF Ab)

16) IgLON family member 5 Ab (IgLON5 Ab)

17) Neurochondrin Antibody (Neurochondrin Ab)

18) Septin-7 Ab (Septin-7 Ab)

19) Anti-glial nuclear antibody type 1 (AGNA-1 Ab)

20) Anti-neuronal nuclear antibody type 1 (Anti-Hu) (ANNA antibody type 1)

21) Anti-neuronal nuclear antibody type 2 (Anti-Ri) (ANNA antibody type 2)

22) Anti-neuronal nuclear antibody type 3 (ANNA antibody type 3)

23) Tripartite motif-containing protein 46 antibody (TRIM46 Ab)

24) Phosphodiesterase 10A Antibody (PDE10A Ab)

Serum Serology

Complement C3 and C4

Complement CH50 functional assay

ANA Screen

Varicella IgM and IgG

CMV IgG and IgM

HIV Screen

Bartonella henselae IgG and IgM

Rubeola IgM

CMV IgG and IgM

Borrelia burgdorferi

Mycoplasma IgG and IgM

Rabies antibody screen

Parvovirus IgG (positive) and IgM were negative

Epstein–Barr virus antibody panel:

VCA IgG: Positive

VCA IgM: Positive

EBNA IgG: Positive

EA-D IgG: Negative

Adults with ADEM tend to have a more severe clinical course and worse outcomes than children, including longer hospital stays, increased need for intensive care, and higher mortality rates [9]. This may be a result of more intense inflammatory responses, greater blood–brain barrier disruption, and a higher likelihood of catastrophic variants such as acute hemorrhagic leukoencephalitis, in which edema, vascular necrosis, and hemorrhage contribute to irreversible brain injury [10]. Prompt recognition of ADEM is particularly crucial in adults and relies on a high index of clinical suspicion, in the context of a preceding infection, followed by multifocal neurological deficits, characteristic neuroimaging findings, and the exclusion of certain alternative diagnoses.

CSF findings in ADEM tend to be non-specific. Early in the course, CSF pleocytosis may show a neutrophilic predominance, shifting to a lymphocytic pattern as the disease progresses. CSF protein is usually only mildly elevated [4].

Early in the course, CT imaging is usually normal. MRI of the brain is the imaging modality of choice, and typical findings include multifocal, bilateral, hyperintense, poorly demarcated white matter lesions on T2-weighted images. These lesions are typically smaller when the MOG antibody is negative, and larger when the antibody is positive in ADEM patients [11]. Spinal cord involvement is described in a third of patients, with large, confluent lesions typically involving multiple segments and more likely to occur in patients with positive MOG antibody [11].

There is considerable overlap between ADEM, acute fulminant multiple sclerosis (MS), myelin oligodendrocyte glycoprotein antibody-associated disorder (MOG-AD), and neuromyelitis optica spectrum disorder (NMOSD) [1]. Although these inflammatory demyelinating disorders arise from distinct pathophysiological mechanisms, they frequently share overlapping clinical features. Notably, ADEM, MOG-AD, and NMOSD are often preceded by recent infections, while fever and encephalopathy are common in ADEM, MOG-AD, and fulminant MS [12]. A positive MOG antibody can be seen with nearly 40% of adults with ADEM [13] and up to 65% of children with ADEM [14]. While ADEM presents as a monophasic illness, MOG-AD typically exhibits a relapsing clinical pattern [15].

On the cusp of adulthood, our patient presented with antecedent EBV infection, fevers, erythema of the oropharynx and lymphadenopathy. She did not have a history of relapsing demyelinating disease. Her clinical presentation (fever, encephalopathy and rapid neurological deterioration), CSF profile, and neuroimaging strongly pointed to ADEM as the underlying diagnosis. Although the CSF findings could be suggestive of meningitis, the imaging features and negative microbiologic studies make this less likely. The size and appearance of the lesions on MRI brain and spine were consistent with a negative MOG antibody; however, this was not sent prior to the patient’s demise. Despite treatment with empiric antimicrobials and high-dose corticosteroids, her condition deteriorated rapidly, progressing to irreversible brain injury within 48 hours of hospitalization.

4. Conclusion

Given its rarity and the absence of adult-specific diagnostic criteria, the diagnosis and management of ADEM in adults remain challenging. Timely MRI of the brain and spine, particularly in patients presenting with focal neurological deficits, may be the most helpful diagnostic modality for distinguishing ADEM from infectious meningitis. This case, along with the existing literature, highlights the need for continued research, increased clinical awareness, and the development of diagnostic criteria tailored to adult patients with ADEM.

Data Availability

The data supporting the findings of this case report is available from the corresponding author upon reasonable request.

Abbreviations

Ab: Antibody;

CSF: Cerebrospinal Fluid;

PCR: Polymerase Chain Reaction;

IgG: Immunoglobulin G;

IgM: Immunoglobulin M;

VDRL: Venereal Disease Research Laboratory;

mNGS: metagenomic Next-Generation Sequencing;

VCA: Viral Capsid Antigen;

EBNA: Epstein-Barr Nuclear Antigen;

EA-D: Early Antigen-Diffuse component.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

[1] Pohl, D., Alper, G., Van Haren, K., Kornberg, A.J., Lucchinetti, C.F., Tenembaum, S., et al. (2016) Acute Disseminated Encephalomyelitis: Updates on an Inflammatory CNS Syndrome. Neurology, 87, S38-S45.[CrossRef] [PubMed]
[2] Schwarz, S., Mohr, A., Knauth, M., Wildemann, B. and Storch-Hagenlocher, B. (2001) Acute Disseminated Encephalomyelitis: A Follow-Up Study of 40 Adult Patients. Neurology, 56, 1313-1318.[CrossRef] [PubMed]
[3] Lucas, J. (1790) An Account of Uncommon Symptoms Succeeding Measles: With Some Additional Remarks on the Infection of Measles and Smallpox. The London Medical Journal, 11, 325-331.
[4] Otallah, S. (2020) Acute Disseminated Encephalomyelitis in Children and Adults: A Focused Review Emphasizing New Developments. Multiple Sclerosis Journal, 27, 1153-1160.[CrossRef] [PubMed]
[5] Krupp, L.B., Tardieu, M., Amato, M.P., Banwell, B., Chitnis, T., Dale, R.C., et al. (2013) International Pediatric Multiple Sclerosis Study Group Criteria for Pediatric Multiple Sclerosis and Immune-Mediated Central Nervous System Demyelinating Disorders: Revisions to the 2007 Definitions. Multiple Sclerosis Journal, 19, 1261-1267.[CrossRef] [PubMed]
[6] Berzero, G., Cortese, A., Ravaglia, S. and Marchioni, E. (2015) Diagnosis and Therapy of Acute Disseminated Encephalomyelitis and Its Variants. Expert Review of Neurotherapeutics, 16, 83-101.[CrossRef] [PubMed]
[7] Hatharasinghe, A., Akhondi, H. and Pepito, D. (2020) Acute Disseminated Encephalomyelitis. HCA Healthcare Journal of Medicine, 1, 77-82.[CrossRef] [PubMed]
[8] Li, K., Li, M., Wen, L., Wang, Q., Ding, X. and Wang, J. (2022) Clinical Presentation and Outcomes of Acute Disseminated Encephalomyelitis in Adults Worldwide: Systematic Review and Meta-Analysis. Frontiers in Immunology, 13, Article 870867.[CrossRef] [PubMed]
[9] Ketelslegers, I., Visser, I., Neuteboom, R., Boon, M., Catsman-Berrevoets, C. and Hintzen, R. (2010) Disease Course and Outcome of Acute Disseminated Encephalomyelitis Is More Severe in Adults than in Children. Multiple Sclerosis Journal, 17, 441-448.[CrossRef] [PubMed]
[10] Anilkumar, A.C., Foris, L.A. and Tadi, P. (2024) Acute Disseminated Encephalomyelitis. StatPearls.
[11] Baumann, M., Sahin, K., Lechner, C., Hennes, E.M., Schanda, K., Mader, S., et al. (2014) Clinical and Neuroradiological Differences of Paediatric Acute Disseminating Encephalomyelitis with and without Antibodies to the Myelin Oligodendrocyte Glycoprotein. Journal of Neurology, Neurosurgery & Psychiatry, 86, 265-272.[CrossRef] [PubMed]
[12] Corbali, O. and Chitnis, T. (2023) Pathophysiology of Myelin Oligodendrocyte Glycoprotein Antibody Disease. Frontiers in Neurology, 14, Article 1137998.[CrossRef] [PubMed]
[13] López-Chiriboga, A.S., Majed, M., Fryer, J., Dubey, D., McKeon, A., Flanagan, E.P., et al. (2018) Association of Mog-Igg Serostatus with Relapse after Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for Mog-IgG-Associated Disorders. JAMA Neurology, 75, 1355-1363.[CrossRef] [PubMed]
[14] Armangue, T., Olivé-Cirera, G., Martínez-Hernandez, E., Sepulveda, M., Ruiz-Garcia, R., Muñoz-Batista, M., et al. (2020) Associations of Paediatric Demyelinating and Encephalitic Syndromes with Myelin Oligodendrocyte Glycoprotein Antibodies: A Multicentre Observational Study. The Lancet Neurology, 19, 234-246.
[15] Gklinos, P. and Dobson, R. (2024) Myelin Oligodendrocyte Glycoprotein-Antibody Associated Disease: An Updated Review of the Clinical Spectrum, Pathogenetic Mechanisms and Therapeutic Management. Antibodies, 13, Article 43.[CrossRef] [PubMed]

Copyright © 2026 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.